RxDoctor Payments Data

Rida Aslam, DO

Gastroenterology · Crown Point, INNPI 1265964944

Payments from drug & device makers

$810in general payments, 2019–2025

Across 26 payments — averaging $31.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • Olympus America Inc.$148
  • Takeda Pharmaceuticals U.S.A., Inc.$106
  • Medtronic$101
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$79
  • Regeneron Healthcare Solutions, Inc.$35
  • plus $101 from 5 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$810 in reported general payments places this provider in the 25th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$85,121
Medicare patients
377
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab11$72,144
CreonLipase/Protease/Amylase14$36,379
LinzessLinaclotide16$11,486
TrulancePlecanatide14$8,779
Mesalamine19$6,723
Dexlansoprazole DrDexlansoprazole19$6,072
Sucralfate12$2,616
Pantoprazole Sodium118$1,320
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl107$1,104
Dicyclomine Hcl13$528
Omeprazole39$447
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl23$358
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl15$195
Lansoprazole15$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$240$47,86530 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$79$8,77914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →